ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Down syndrome (DS) is the most common genetic cause of Alzheimer's disease (AD). As individuals with DS live longer, the prevalence of AD-related dementia increases, underscoring a growing public health concern. Historically, research efforts have largely overlooked the early manifestations and neuropathological trajectory of AD in DS, limiting our understanding of how closely it mirrors or diverges from sporadic AD in the general population. The Alzheimer's Disease Research Center (ADRC) network, supported by the National Institute on Aging (NIA), plays a critical role in addressing this gap. This paper highlights the experiences of two ADRCs-University of California, Irvine (UCI) and University of Kansas Medical Center (KU) in developing dedicated research cores focused on aging and AD in individuals with DS. We describe cohort characteristics, outcome measures, major scientific contributions, and the challenges and opportunities that have emerged in this specialized area of research. HIGHLIGHTS: Down syndrome (DS) is the most common genetic cause of Alzheimer's disease (AD). People with DS benefit from inclusion into the Alzheimer's Disease Research Center (ADRC) network. Clinical, cognitive, neuroimaging, and fluid biomarkers research inclusive of people with DS is feasible and encouraged. This review highlights the research of two sites and lessons learned from including people with DS in the ADRC ecosystem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.